– Collaborate to accelerate the treatment of next-generation cancer –
TOKYO and CAMBRIDGE, Mass., June 1, 2022 / PRNewswire / – Astellas Pharma Inc. (TSE: 4503, President and CEO: Candy YasukovaPh.D., “Astellas”) and GO Therapeutics, Inc. (co-founder and CEO: Constantine Theodore“GO”) today announced that Xyphos Biosciences, Inc. (a subsidiary of Astellas, “Xyphos”) and GO have entered into a strategic research collaboration and licensing agreement to develop new immuno-oncology therapies.
GO is applying new advances in glycoproteomics to develop therapeutic anti-cancer agents based on antibodies that specifically target cancer cells. Xyphos holds a new and patented ACCELTM a technology platform that uses it convertibleCAR® (convertible chimeric antigen receptor) on immune cells.
Under the terms of the agreement, the two companies will work together solely to detect new antibodies with high affinity for two different glycoprotein targets and apply those antibodies to a number of therapeutic methods. GO will lead the collaboration to detect high-affinity antibodies against the two targets, and Astelos will be responsible for the research, clinical development, and commercialization of therapeutic agents derived from antibodies provided by GO.
Under the terms of the agreement, Xyphos will pay GO Therapeutics $ 20.5 million advance cash. The amount of payments for stages and contingencies can reach another 763 million US dollars.
“We are pleased to work with Astellas to develop a new class of immuno-cancer therapies,” he said. Constantine Theodore, co-founder and CEO of GO Therapeutics. “The combination of GO targets and antibodies and ACCEL technology from Astellas promises to create a new generation of cancer treatments that have a higher therapeutic index. This will allow oncologists to increase the effectiveness of antibody-based immunotherapy in solid tumors with less damage to healthy tissue.”
Naoki AkamuraDirector of Strategy at Astellas said: “At Astellas, we have positioned immunoancology as one of the main areas of our research and development strategy. We believe this collaboration will bring synergies between the two companies’ cutting-edge research and ultimately lead to the development of new therapies for patients with great unmet medical needs ”.
About GO Therapeutics
GO Therapeutics uses the latest advances in glycobiology to create more potent and less toxic cancer drugs. Cancer-specific GO Therapeutics antibodies against tumor-specific antigens can be used in multimodal approaches to cancer destruction, such as antibody-drug conjugates, bispecific T cells involved, and immune-based cell therapy. The company’s research team includes some of the leading researchers and applied biologists in the field of glycoproteomics. GO Therapeutics is based in Cambridge, Massachusetts For more information about the company, please visit https://gotherapeutics.com/.
About Xyphos Biosciences, Inc., Astellas.
Xyphos Biosciences, Inc., located at Southern San Francisco, Californiais a subsidiary of Astellas with ACCELTM technology, the CAR (chimeric antigen receptor) technology platform for the treatment of immune cells. DISCOVERTM The technology combines a universal CAR on immune cells such as natural killers (NK) or T cells (convertibleCAR® cells) with molecules based on bispecific antibodies (MicAbodies) to direct the function of immune cells against cancer cells. By replacing or using multiple MicAbodies according to the characteristics of the cancer cells to be attacked, convertibleCAR® cells can recognize different cancer antigens or multiple cancer antigens and attack different cancer cells. Xyphos Biosciences was launched in 2017, and the company was acquired by Astellas Pharma in December 2019. For more information about the company, please visit www.xyphosinc.com.
Astellas Pharma Inc. is a pharmaceutical company that does business in more than 70 countries. We are advancing a focus area approach that is designed to identify opportunities for the ongoing development of new drugs to treat diseases with high unmet medical needs, focusing on biology and modality. In addition, we are also looking beyond our main focus on Rx to create Rx +® Healthcare solutions that combine our expertise and knowledge with cutting-edge technology in a variety of external partner areas. Through these efforts, Ostelos is at the forefront of healthcare change to turn innovative science into value for patients. For more information, visit our website at https://www.astellas.com/en.
In this press release, statements made regarding current plans, assessments, strategies and beliefs, as well as other statements that are not historical facts, are forward-looking statements about Astellas ’future performance. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it, and include known and unknown risks and uncertainties. A number of factors may lead to the fact that the actual results differ significantly from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and laws and regulations concerning pharmaceutical markets, (ii) exchange rate fluctuations, (iii) delays in the release of new products, (iv) the inability of Astellas effectively market existing and new products, (v) the inability of Astellas to continue to effectively research and develop products adopted by customers in highly competitive markets, and (vi) infringement of Astellas’ intellectual property rights by third parties. The information about pharmaceutical products (including products currently under development) that is included in this press release is not intended as advertising or medical advice.
See original content for multimedia downloads:https://www.prnewswire.com/news-releases/astellas-and-go-therapeutics-enter-into-strategic-research-and-license-agreement-to-develop-novel-antibodies-for-immuno-oncology- 301558512.html
SOURCE Astellas Pharma Inc .; GO Therapeutics, Inc